Abstract. To determine whether the slope of a maximal bronchial challenge test (in which FEV 1 falls by over 50%) could be extrapolated from a standard bronchial challenge test (in which FEV 1 falls up to 20%), 14 asthmatic children performed a single maximal bronchial challenge test with methacholine (dose range: 0.097-30.08 mol) by the dosimeter method. Maximal dose-response curves were included according to the following criteria: (1) at least one more dose beyond a ⌬FEV 1 ജ 20%; and (2) a MFEV 1 ജ 50%. PD 20 FEV 1 was calculated, and the slopes of the early part of the dose-response curve (standard dose-response slopes) and of the entire curve (maximal dose-response slopes) were calculated by two methods: the two-point slope (DRR) and the least squares method (LSS) in % ⌬FEV 1 × mol −1 . Maximal dose-response slopes were compared with the corresponding standard dose-response slopes by a paired Student's t test after logarithmic transformation of the data; the goodness of fit of the LSS was also determined. Maximal dose-response slopes were significantly different (p < 0.0001) from those calculated on the early part of the curve: DRR 20% (91.2 ± 2.7 ⌬FEV 1 % ⅐ mol −1 ) was 2.88 times higher than DRR 50% (31.6 ± 3.4 ⌬FEV 1 % ⅐ mol −1 ), and the LSS 20% (89.1 ± 2.8% ⌬FEV 1 ⅐ mol −1 ) was 3.10 times higher than LSS 50% (28.8 ± 1.5% ⌬FEV 1 ⅐ mol −1 ). The goodness of fit of LSS 50% was significant in all cases, whereas LSS 20% failed to be significant in one. These results suggest that maximal dose-response slopes cannot be predicted from the data of standard bronchial challenge tests.
Introduction
Bronchial hypersensitivity to inhaled pharmacologic agents such as methacholine and histamine is one of the hallmarks of asthma. This means that in asthmatic patients the provocative dose (PD) or concentration (PC) that induces a 20% fall in the FEV 1 is lower than in normal subjects. Although PD and PC are the indexes used most commonly in bronchial challenge tests, giving information about the degree of bronchial sensitivity to the inhaled agent [6, 11, 32] , it is not possible to describe the severity of airway narrowing, based on these parameters alone. This means that asthmatics with similar PDs may reach different degrees of airway obstruction if further doses are inhaled. Thus, the degree of airway sensitivity to a pharmacologic agent provides only a partial information about the severity of bronchial hyperresponsiveness. Furthermore, the effects of antiasthma drugs such as inhaled corticosteroids are frequently monitored by bronchial challenge tests with methacholine and histamine, and PD and PC are the parameters chosen to express the results; however, these changes are often very small [5, 33] .
In 1993, the European Respiratory Society (ERS) [29] published recommendations for bronchial challenge tests, indicating that complete information from a bronchial challenge test with pharmacologic agents can only be obtained from analysis of the shape of the dose-response curve (DRC). It is clearly stated in this report that, although PD or PC indicates the position of the DRC, the slope and the degree of maximal obstruction provide relevant information about the level and potential severity of bronchial response [9, 27, 29] . Woolcock et al. [34] were the first to demonstrate that the shape of DRC in asthmatics was different from that of normals, i.e. many asthmatics show a higher slope and a higher maximal response or plateau when exposed to high doses of methacholine, histamine, or other inhaled bronchoconstrictors [2, 15, 21, 22, 24] . However, although the ERS report [29] considered that maximal DRCs, mandatory for the study of maximal response, can be safely recorded up to a 50% decline in FEV 1 , provided the patients have normal baseline lung function, it is also recommended that this procedure should be limited to research studies. Thus, in a clinical setting, most of the information that can be obtained from bronchial challenge tests with pharmacologic agents comes from the analysis of the early part of the DRC.
Moderate and severe asthmatics are characterized by excessive bronchial narrowing. Such patients do not usually exhibit the stable response (plateau) common in normal subjects or patients with mild asthma. Consequently, in the absence of a plateau, the dose-response slope (DRS) is the only index that may be used to describe the shape of DRC and hence the severity of bronchial response. Although its main application is for epidemiologic studies, the DRS has also been used in clinical [3, 25] and pathophysiologic research [7, 31] , which often includes the study of patients with moderate to severe asthma. However, there is still some controversy concerning the methods used to calculate and analyze the DRS. First, different groups use different methods to estimate the slopes, and there is no one single model that provides the best fit to all DRCs of asthmatics. Second, although it is known that a linear relationship can be inaccurate in describing the shape of DRCs, the more frequently used methods are the simple linear regression [1, 10, 24, 34] using the least-squares method and the dose-response ratio, or two-point slope, first described by O'Connor et al. [17] . Third, the slope is more often determined on standard DRCs (SDRCs) [2, 3, 15, 17, 21, 22, 34] than in maximal DRCs (MDRCs) even in clinical settings [7, 14, 31, 34] , and it is not yet clear which portion of the DRC is most important. Although different mathematical models [2, 9, 10, 17, 28, 31] have been used to describe and/or predict the shape of individual DRCs, we are not aware of any studies determining whether the linear slope of the DRC in asthmatic patients changes significantly when high doses of methacholine are inhaled.
The aim of this study was to determine whether the slope of a maximal bronchial challenge test (in which FEV 1 falls by more than 50%) could be extrapolated from a standard bronchial challenge test (in which FEV 1 falls up to 20%). This may be relevant when deciding whether standard or maximal bronchial challenge tests should be chosen if the slope is used to monitor the degree of bronchial hyperresponsiveness in clinical research protocols.
Materials and Methods

Study Subjects
The data on the subjects included in the present study are summarized in Table 1 . Fourteen asthmatic children (five females and nine males), aged 9-17 years, whose parents gave their consent after an oral explanation about the protocol, were included. According to their clinical symptoms and/or the daily medication required, ten patients were classified as having moderate to severe asthma, and four were labeled as mild persistent [16] . At the time of the test, all children were clinically stable and free from upper respiratory infections for at least 6 weeks. Baseline FEV 1 , determined as described below, was >70% of the predicted value (Table 1) . Inhaled bronchodilators and oral theophylline compounds, when used, were withheld at least 8 and 12 hr, respectively, before the test [29] . Five patients were taking daily inhaled corticosteroids, two cromolyn sodium and two ketotifen, and this treatment was maintained.
Study Design
All children performed a single bronchial challenge test with methacholine. Double doses of methacholine were administered with a dosimeter up to a 50% reduction compared with the postsaline FEV 1 or until a plateau response was reached. To determine if the degree of airway obstruction to high doses of methacholine could be predicted from a standard bronchial challenge test, the slopes of MDRC were compared with those obtained on the early part of the same dose-response curve (SDRC). The slopes were calculated by two methods: the two-point slope or dose-response ratio (DRR) as described by O'Connor et al. [17] , and the least squares method (LSS).
The study design was approved by the Scientific Council of the Faculty of Medical Sciences, as part of a master's thesis.
Methacholine Challenge Test
Forced expiratory maneuvers were measured using a pneumatocograph (model Compact, Vitalograph, Buckingham, England). Baseline and postchallenge FEV 1 were recorded as the maximum of three consecutive measurements that agreed with each other within 5%.
The methacholine challenge test was performed using a modified dosimeter method [8] , following the European Respiratory Society recommendations [29] . Aerosols were delivered from a dosimeter (model MB3 Mefar, Brescia, Italy) at 20 p.s.i., with an airflow of 8 liters/min and with a nebulizer output of 30.8 l/five puffs of 0.6 s each. After inhalation of saline, and if the FEV 1 postsaline fell no more than 10% from baseline value, double cumulative doses of methacholine chloride ranging from 0.097 to 30.08 mol were administered. The aerosols were inhaled by fast inspiratory maneuvers from functional residual capacity (FRC) to total lung capacity (TLC), without breath holding. All subjects wore a nose clip during aerosol inhalation and spirometry. Measurements of FEV 1 postchallenge were performed 90 s after saline and after each dose of methacholine. The test was interrupted if one of the following occurred: (1) a FEV 1 decline ജ50%; (2) a plateau was reached, i.e., when the last two response values showed a variation of less than 5% between each other; (3) at the subject's request due to respiratory symptoms; or (4) after the last dose (30.08 mol) had been given.
Airway sensitivity was expressed as the PD 20 FEV 1 , obtained from the semilogarithmic DRC by linear interpolation of the last two points, according to the formula recommended by ERS [29] .
Maximal bronchoconstrictor response (MFEV 1 ) was expressed as the maximal percentage fall in FEV 1 [29, 34] ; otherwise, whenever the response reached a plateau the data points on the plateau were averaged [30] [31] [32] .
Data Analysis
The curves were included in the statistical analysis according to the following criteria: (1) at least one more dose beyond a FEV 1 reduction ജ20%, and (2) a MFEV 1 ജ50% without plateau.
Least Squares Slope
As shown in Figure 1 , methacholine DRSs were determined by the LSS in two ways: (1) with all data points of MDRCs (LSS 50% ) from the first to the last cumulative dose or to the first cumulative dose at which a plateau response ജ50% was reached [7] ; and (2) from the first dose of methacholine to the cumulative dose at which FEV 1 reduction was ജ20% from postsaline value (LSS 20% ) [10] . Only the LSS with at least three data points were included in the analysis.
Two-point Slope (DRR)
The slope of the straight line between the origin and the final cumulative dose was also determined by the simplified formula (Equation 1), the two-point slope or DRR proposed by O'Connor et al. [17] : 
Statistical Methods
The goodness of fit of LSS was expressed by the coefficient of determination r 2 , and the linear regression was considered significant if p < 0.05. The median of the number of points included in the calculation of LSS 20% and LSS 50% was also determined.
A Kolmogorov-Smirnov one-sample test was used to compare the distributions of the LSS and DRR with the normal distribution, and the Levene test was applied to test the homogeneity of variances. After logarithmic transformation (log 10), the distributions of the maximal and standard DRS in this group were not significantly different from the normal, and the variances between groups (DRR 20% and DRR 50% ; LSS 20% and LSS 50% ) were homogeneous. Paired Student's t tests were performed to compare the slopes of the SDRC with those determined using all data points in the MDRC: (1) LSS 20% with LSS 50% and (2) the standard dose-response ratio (DRR 20% ) with maximal dose-response ratio (DRR 50% ). The differences were considered statistically significant if p < 0.05.
After statistical analysis, the results were recalculated into the standard form and the results expressed as geometric mean ± S.D.
Results
From Table 1 it is apparent that all children tested had hypersensitivity to methacholine (range PD 20 , 0.03-3.76 mol), and 12 reached a FEV 1 decline ജ50%. Two subjects were excluded. In subject 4 the test was stopped because of breathlessness, and subject 13 reached a plateau at 30%. Therefore, it was possible to compare the slopes in 12 subjects, whose individual DRC are shown in Figure 2 .
In Table 2 it is shown that the coefficients of determination of LSS 20% and LSS 50% were all above 0.80. LSS 50% reached statistical significance (p < 0.05) in all cases, whereas LSS 20% failed to be significant in just one case, with only three points included in the regression. Since there were no zero or negative slopes, there was no need to add a constant prior to the logarithmic transformation.
Comparison of MDRS with SDRS
The individual values of MDRS and SDRS calculated by both methods are represented in Figure 3 . MDRSs were significantly different (p < 0.0001) from those determined in the early part of the same DRC. The slopes calculated on the early part of the DRC were higher than MDRS, both with the DRR [DRR 20% (91.2 ± 2.7 % ⌬FEV 1 × mol −1 ) was 2.88 times higher than DRR 50% (31.6 ± 3.4 ⌬FEV 1 % × mol −1 )] and with the LSS [LSS 20% (89.1 ± 2.8 % ⌬FEV 1 × mol −1 ) was 3.1 times higher than LSS 50% (28.8 ± 1.5 % ⌬FEV 1 × mol −1 )]. 
Discussion
The purpose of the present study was to determine if MDRS could be extrapolated from the slope of a standard bronchial challenge test, which is still the recommended procedure to evaluate the degree of bronchial hyperresponsiveness in clinical and epidemiologic protocols. From the analysis of this group of asthmatic children it was clear that the degree of airway narrowing induced by a maximal bronchial challenge test with methacholine could not be predicted from the slopes determined in the early part of the same MDRC. The following differences between SDRS and MDRS were observed with both methods of calculation of the slopes. First, both mean DRR 20% and LSS 20% (standard slopes) overestimated almost by three times the slopes measured on the same DRC using all data points up to a fall of 50% or more from baseline (maximal slopes). Second, although these methods of assessing the DRC are oversimplified because both assume that the dose-response relationship is linear, the analysis of the goodness of fit of LSS in this group of asthmatics showed that the coefficients of determination (r 2 ) of LSS 20% and LSS 50% were all above 0.80. The LSS 50% reached statistical significance in all cases, whereas LSS 20% failed to be significant in only one. The low grade of significance found in this case was probably due to an insufficient number of data points included in the calculation (three points). Thus, although the relationships between increasing doses of methacholine and the severity of airway response may have changed during the test and the methods of calculating the slopes are still open to debate [1, 2, 10, 12, 23, 26, 28] , these results suggested that a linear model can be used to calculate this index of bronchial hyperresponsiveness in asthmatic patients. In fact, the linear model is the most frequently used not only in epidemiologic [1, 4, 7, 18, 24] but also in research protocols [3, 13, 15, 19, 34] . The mean values of DRR 20% measured in our group of patients were well above the cutoff levels between normals and asthmatics, established with the same method of calculation by Peat et al. [21] and by Backer [4] in epidemiologic studies in children. However, these values were obtained from standard bronchial challenge tests with histamine, and it is still not known if the slopes of DRC to histamine and methacholine in children are comparable [20, 27] . Concerning the least squares method, the LSS 20% values found in the present study were similar or higher than the mean values calculated by Chinn et al. [10] in adult subjects with symptoms of asthma, and the LSS 50% were within the same range as those measured in clinical trials of adult asthmatic subjects [3, 25] .
To our knowledge, no other studies have compared SDRS with MDRS using the present methods. This may be because most of the maximal bronchial challenge tests were performed in mild asthmatics who usually exhibited a reproducible plateau response, which is generally accepted to describe the shape of DRC. Beyond its usefulness in epidemiologic studies, thus avoiding the censoring of data, other groups have used the slope together with PD and/or plateau to monitor the effects of inhaled antiinflammatory drugs [3, 25] or natural antigenic exposure in bronchial reactivity of asthmatics and subjects with allergic rhinitis [7] . In this kind of research, where moderate and severe asthmatics might be included, the slope may be the only additional parameter available to describe the shape of DRC. Since the slope is measured on the steepest part of the DRC, the differences between SDRS and MDRS are expected to be even higher in more severe asthmatics without plateau than in normal subjects or patients in whom a stable response is obtained.
Our results suggest that MDRS is the closest measurement of the potential severity of airway hyperresponsiveness which can be obtained from an artificial situation such as a bronchial challenge test when a plateau response is absent.
Finally, of the 14 selected asthmatic children, 12 reached a FEV 1 decline of 50% or more from postsaline and exhibited excessive airway narrowing without plateau, and so the analysis of the shape of DRC could only be provided by PD 20 FEV 1 and slope. These results were obtained with cumulative doses of methacholine ranging between 0.117 and 30.08 mol, well below those administered to mild asthmatics and normal subjects in maximal bronchial challenge tests. Higher doses of methacholine should be included in future protocols to study the pathophysiology of maximal airway narrowing.
In conclusion, in this group of asthmatic children the slopes of MDRC could not be extrapolated from the early part of DRC. Even though it is not clear which segment of the slope is more important as a marker of hyperresponsiveness, this should be taken into account when planning clinical research protocols.
